Êײ¿¡¶ÖйúÌØÓ¦ÐÔƤÑ×»¼ÕßÉú´æ×´¿öµ÷Ñб¨¸æ¡··¢²¼
ÉϺ£2020Äê8ÔÂ5ÈÕ /ÃÀͨÉç/ -- ½ñÈÕ£¬Öйú½¡¿µ´Ù½øÓë½ÌÓýлáÁªºÏÈüŵ·ÆÖйúÐû²¼£ºÊײ¿¡¶ÖйúÌØÓ¦ÐÔƤÑ×»¼ÕßÉú´æ×´¿öµ÷Ñб¨¸æ¡·Õýʽ·¢²¼¡£¾¹ý½ü°ëÄêµÄµ÷ÑÐÓëÊý¾ÝÕûÀí£¬±¨¸æÊ״ξ۽¹ÓÚÖÐÖضÈÌØÓ¦ÐÔƤÑ×»¼ÕßÕâһȺÌ壬չÏÖÁËÎÒ¹úÌØÓ¦ÐÔƤÑ×»¼ÕßµÄÕæʵÉú´æÏÖ×´£º³¬¹ý75%µÄÒ½Éú¶ÔÏÖÓÐÖÎÁÆ·½°¸²»ÂúÒ⣻¶àÊý»¼ÕßÒòðþÑ÷¶ø˯ÃßÀ§ÄÑ£¬¼õÉÙðþÑ÷Ö¢×´ÊÇ75.8%ÖÐÖضȻ¼ÕßµÄÆÈÇÐÐèÇó£»»¼Õß·¢²¡ÄêÇᣬ²¡³Ìƽ¾ù½ü10Ä꣬ÕûÌåÊÜÓ°ÏìƤËðÃæ»ý³¬¹ý30%£»³¬10%»¼Õß´æÔÚ×ÔɱÇãÏò£»ÓÐ71.2%µÄ»¼ÕßÔøÔâÊܹý±»ÆçÊӵľÀú¡£¶øÔÚ½üÆÚ£¬Ê׸öÖÎÁƳÉÈËÖÐÖضÈÌØÓ¦ÐÔƤÑ׵İÐÏòÉúÎïÖƼÁ´ï±ØÍ× ®ÒÑÔÚÈ«¹úÈ«ÃæÉÏÊУ¬Îª°ïÖú¸ü¶à»¼Õß¼õÇᾼøºµ££¬Èüŵ·ÆÖйúÁªºÏþÐŽ¡¿µÆô¶¯ÁË¡°¹Ø°®±Ø´ï¡±»¼Õ߹ذ®ÏîÄ¿£¬ÓÚ½ñÈÕͬ²½¹«²¼ÁËÏîĿϸÔò£¬Í¨¹ý´´ÐµÄÖ§¸¶»úÖÆ£¬Èøü¶à»¼Õß»ñµÃÓÐЧ¡¢¹æ·¶µÄÖÎÁÆ¡£
ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»áµÚ13½ìÖ÷ÈÎίԱ¡¢±±¾©´óѧÈËÃñҽԺƤ·ô¿ÆÖ÷ÈÎÕŽ¨ÖнÌÊÚ
×÷Ϊ´Ë´Îµ÷ÑÐÏîÄ¿µÄ·¢ÆðÈËÖ®Ò»£¬ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»áµÚ13½ìÖ÷ÈÎίԱ¡¢±±¾©´óѧÈËÃñҽԺƤ·ô¿ÆÖ÷ÈÎÕŽ¨ÖнÌÊÚ±íʾ£º¡°ËäÈ»ÌØÓ¦ÐÔƤÑ×ÔÚÁÙ´²ÉÏÊǺܳ£¼ûµÄƤ·ô²¡£¬µ«¹ýÈ¥ÎÒ¹úÒ½Éú¶ÔÆäÈÏ֪ȴ²»¹»ÍêÉÆ£¬ÁÙ´²Õï¶ÏÂÊÒ²Ïà¶Ô½ÏµÍ¡£¹ú¼Êµ÷²éÏÔʾ£¬ÌØÓ¦ÐÔƤÑ×ÔÚ·ÇÖÂÃüÐÔƤ·ô¼²²¡Öм²²¡¸ºµ£Î»ÁеÚÒ»¡£ÎÒÃÇÏ£Íû½èÖú±¾´Îµ÷ÑнøÒ»²½Ìá¸ßÖйúÌØÓ¦ÐÔƤÑ×¼²²¡ÈÏÖª¡¢ÕïÁÆˮƽÓëÉç»á±£ÕÏ£¬Íƶ¯Õþ²ß³ÖÐø¹Ø×¢ÓëÖ§³Ö£¬È«Ãæ°ïÖú»¼ÕßÌáÉýÉú»îÖÊÁ¿¡£ÎÒÃǷdz£ÐÀϲµØ¿´µ½´´ÐÂÉúÎïÖƼÁ´ï±ØÍ× ®µÄÉÏÊÐΪ»¼Õß´øÀ´¸£Òô£¬Äܹ»Ç¿Ð§¡¢¿ìËÙ¡¢³ÖÐøµØ»º½âðþÑ÷¡¢Ïû³ýƤËðµÈÖ¢×´[1],[2],[3],[4]£¬ÇÒÆäÓÐЧÐԺͰ²È«ÐÔÒÑ»ñ¶àÏîÁÙ´²Ñо¿¼°ÕæʵÊÀ½çÑо¿Ö¤Êµ¡£¡±
¾çÁÒðþÑ÷¼°¹²²¡¸ºµ£ÑÏÖØ£¬ÔÚ·ÇÖÂÃüÐÔƤ·ô¼²²¡Öм²²¡¸ºµ£Î»ÁеÚÒ»
ÖÐÖضÈÌØÓ¦ÐÔƤÑ×£¨atopic dermatitis£¬AD£©ÊÇÒ»ÖÖÄÑÖÎÐÔ¡¢¸´·¢ÐÔ¡¢Ñ×Ö¢ÐÔƤ·ô²¡£¬ÒÔ·´¸´·¢×÷µÄ¾çÁÒðþÑ÷ºÍƤÕîΪÖ÷ÒªÁÙ´²±íÏÖ£¬»¼Õß³£ºÏ²¢¹ýÃôÐÔ±ÇÑס¢Ïø´µÈÆäËûÌØÓ¦ÐÔ¼²²¡¡£ÃÀ¹ú³ÉÈËÌØÓ¦ÐÔƤÑ׵ķ¢²¡ÂÊԼΪ2-5%[5]£¬Ä¿Ç°ÎÒ¹úÉÐȱ·¦È«¹úÐԵĸßÖÊÁ¿Á÷Ðв¡Ñ§Êý¾Ý£¬ÌØÓ¦ÐÔƤÑ×µÄÕï¶ÏÂÊÒ²½ÏµÍ¡£¾Ý¹ÀË㣬ÖйúÌØÓ¦ÐÔƤÑ×»¼²¡ÈËÊýԼΪǧÍò¡£ÓɾçÁÒðþÑ÷ÒýÆðµÄ˯Ãßȱʧ¼°ÐÄÀíÎÊÌâÑÏÖØÓ°Ïì×Å»¼ÕßÉú»îÖÊÁ¿£¬Í¬Ê±Ò²¸ø»¼Õß¼ÒÍ¥ºÍÉç»á´øÀ´¾Þ´óµÄ¾¼Ã¸ºµ£¡£
´Ë´ÎÌØÓ¦ÐÔƤÑ×»¼ÕßÉú´æ×´¿öµ÷ÑÐͨ¹ý»¥ÁªÍøµ÷²éÎʾíµÄÐÎʽ½øÐУ¬¹²ÓÐ275ÃûƤ·ô¿ÆÒ½Éú¼°1,362ÃûÖÐÖضÈÌØÓ¦ÐÔƤÑ×»¼Õß²ÎÓ룬½ü90%µÄ»¼Õß18ËêÒÔÉÏ£¬ÇÒÊܽÌÓý³Ì¶È¸ß£¬ÊÇÉç»áÖмáÁ¦Á¿¡£±¨¸æº¸Ç¼²²¡Ìص㡢ÕïÁÆÏÖ×´¡¢ÐÄÀí¸ºµ£¡¢¾¼Ã¸ºµ£µÈ¶à¸öά¶È£¬ÓÉÁÙ´²Ñ§»á¡¢Ñо¿»ú¹¹ºÍ»¼Õß×éÖ¯µÈ¶à·½²ÎÓ룬ÌṩÁË»¼ÕßÉú´æÖÊÁ¿ºÍÁÙ´²ÕïÁÆδ±»Âú×ãÐèÇóµÄ×îÕæʵµÄµÚÒ»ÊÖÊý¾Ý¡£
¼²²¡Ìص㣺Ƶ·±¡¢³ÖÐøºÍÇ¿ÁÒµÄðþÑ÷ÊÇÖÐÖضÈÌØÓ¦ÐÔƤÑ׵ĵäÐÍÖ¢×´£»·¢²¡ÄêÇᣬ¹ý°ëÊýÊܷû¼ÕߵĵÚÒ»´ÎÈ·ÕïÄêÁäСÓÚ20Ëꣻ²¡³Ì³¤£¬ÊܷõĻ¼ÕßÊÜÌØÓ¦ÐÔƤÑ×À§ÈÅƽ¾ù½ü´ï10Ä꣬»¼ÕßµÄÕûÌåÊÜÓ°ÏìƤËðÃæ»ý³¬¹ý30%¡£
ÕïÁÆÏÖ×´£º¼õÉÙðþÑ÷Ö¢×´ºÍƤÕ¿ì»Ö¸´ÊÇÌØÓ¦ÐÔƤÑ×ÖÐÖضȻ¼Õß×îÆÈÇеÄÖÎÁÆÐèÇó¡£75.7%µÄÒ½ÉúÈÏΪÏÖÓÐÖÎÁÆ·½°¸µÄÖÎÁÆЧ¹û²î¼°²»Á¼·´Ó¦¶à£»33%µÄ»¼ÕßÏ£ÍûʹÓø±×÷ÓÃÉÙµÄÒ©Îï¡£
Éç»á¼°Ò½ÁƸºµ£³ÁÖØ£º¹ýÈ¥Ò»Ä꣬ÓÐ22%µÄ»¼ÕßÖÎÁÆÌØÓ¦ÐÔƤÑ×µÄÄêÖ§³ö´óÓÚ12,000Ôª£¬68.7%µÄ»¼ÕßÒ»¸öÔÂÄÚƽ¾ùÇ°ÍùÃÅÕï1-3´Î£¬¶øËùÓвÎÓëµ÷ÑеĻ¼ÕßÔÚÒ»ÄêÖеÄƽ¾ùÃÅÕï´ÎÊý´ïµ½29´Î¡£
¹¤×÷Éú»îÊÜÀ§£¬ÐÄÀíÎÊÌâ²»ÈݺöÊÓ£ºÓÐ46.5%µÄÖضȻ¼ÕßÎÞ·¨¹¤×÷ºÍѧϰ£¬45.8%µÄÖضȻ¼ÕßÄÑÒÔ½øÐÐÕý³£Éç½»»î¶¯£¬ÈÏΪ×ÔÉíûÓÐÎüÒýÁ¦£¬È±·¦×ÔÐÅ£¬ÉõÖÁÓг¬¹ý10%µÄ»¼ÕßÓйý×ÔɱÄîÍ·£¬½ü2%µÄ»¼Õßʵʩ¹ý×ÔɱÐÐΪ¡£
´óÖÚ¶Ô¼²²¡ÈÏÖª²»×㣺ÓÐ71.2%µÄ»¼ÕßÔâÊܹý±»ÆçÊӵľÀú£¬ÆäÖÐ63%µÄ»¼ÕßÔøÔÚ¹«¹²³¡ºÏ±»ÈË×¢ÊÓ¡¢±»ÆçÊÓ£¬»¹ÓÐ42%µÄ»¼Õß±»ÈÏΪÊÇ´«È¾²¡£¬²»ÉÙ»¼ÕßÔøÒòÌØÓ¦ÐÔƤÑ×±»ËûÈ˾ܾøÎÕÊÖ¡¢½Ó´¥ºÍ·þÎñ¡£
ÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôлªÒ½ÔºÆ¤·ô¿ÆÖ÷ÈΡ¢¹ú¼ÊÌØÓ¦ÐÔƤÑ×ÀíÊ»ᣨIEC£©ÀíÊÂÒ¦Ö¾ÈÙ½ÌÊÚ
ÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôлªÒ½ÔºÆ¤·ô¿ÆÖ÷ÈΡ¢¹ú¼ÊÌØÓ¦ÐÔƤÑ×ÀíÊ»ᣨIEC£©ÀíÊÂÒ¦Ö¾ÈÙ½ÌÊÚÔÚ·¢²¼»áÉϱíʾ£º¡°³ÁÖصļ²²¡¸ºµ£¡¢¼«¶ÈµÄ¾«ÉñѹÁ¦ºÍ¹«ÖÚÈÏÖªµÄȱ·¦¼¸´óÎÊÌâؽÐèÒýÆð¹Ø×¢¡£ÁÙ´²Ò½ÉúÓ¦¸ÃÈû¼ÕßÁ˽âÌØÓ¦ÐÔƤÑ×ÐèÒª³¤ÆÚÖÎÁƺ;«ÐĹÜÀí¡£´ËÍ⣬»¹Ó¦Ïò»¼ÕßÇ¿µ÷¹æ·¶ÖÎÁƵÄÖØÒªÐÔ£¬ÄÍÐĵÄÒ½»¼¹µÍ¨£¬¿ÉÒÔÈû¼Õ߸ü»ý¼«µØÅäºÏÕï¶ÏÖÎÁÆ¡£³ý´ËÖ®Í⣬Éç»á¸üÓ¦¸øÓèÌØÓ¦ÐÔƤÑ×»¼Õ߸ü¶àµÄÐÄÀí¹Ø»³£¬¼õÇỼÕߵľ«Éñ¸ºµ££¬Í¬Ê±»¹Ó¦¼ÓÇ¿´óÖڵĽ¡¿µ½ÌÓý£¬¼õÉÙ¶ÔÌØÓ¦ÐÔƤÑ×»¼ÕßµÄÆçÊÓ¡£¡±
´´ÐÂÉúÎïÖƼÁ¡°ÉÁµç¡±ÉÏÊУ¬´´ÐÂÖ§¸¶·½Ê½Ï¸Ôò¹«²¼
¾Ýר¼Ò½éÉÜ£¬È±·¦°²È«ÓÐЧÇҿɳ¤ÆÚʹÓõÄÖÎÁÆÊÖ¶ÎͬÑùÊÇÌØÓ¦ÐÔƤÑ×»¼ÕßÃæÁÙµÄÒ»´óÄÑÌ⣬ĿǰÌØÓ¦ÐÔƤÑ×µÄÖÎÁÆ·½·¨ÊǸù¾Ý²¡È˵IJ¡ÇéÀ´Öƶ¨£¬ÒÔÍⲿÓÃÒ©Èç¾Ö²¿ÍâÓÃÌÇƤÖʼ¤ËØ£¬¿Ú·þÌÇƤÖʼ¤ËغÍÃâÒßÒÖÖƼÁΪÖ÷£¬µ«ÊÇ¿Ú·þÌÇƤÖʼ¤ËغÍÃâÒßÒÖÖƼÁÖÎÁÆÊÇÒ»°ÑË«Èн££¬³¤ÆÚÓÃÒ©¿ÉÄÜ»á´øÀ´¸±·´Ó¦£¬ÁÙ´²ÈÔȱ·¦ÓÐЧÇÒ°²È«µÄÊֶΡ£
ÌØÓ¦ÐÔƤÑ×»¼Õß»¥ÖúÁªÃË¡°ÖйúADÖ®¼Ò¡±µÄ·¢ÆðÈËÊ·ÐÇÏè·ÖÏíÁ˹ã´ó»¼ÕßµÄÐÄÉù£º¡°ÌØÓ¦ÐÔƤÑ×´øÀ´µÄ¾çÁÒðþÑ÷ÒÔ¼°Éç»á»·¾³ºÍ×Ô¼ºÄÚÐĵÄË«ÖØѹÁ¦£¬Ã¿Ê±Ã¿¿Ì¶¼ÔÚÌôÕ½×Å»¼ÕßµÄÉíÌå¡¢ÇéÐ÷ºÍÐÄÀí״̬£¬ÈÃÎÒÃÇÎÞ·¨ÏñÆÕͨÈËÒ»ÑùÕý³£Éú»î¡¢Ñ§Ï°ºÍ¹¤×÷¡£ÏÖÔÚÎÒÃÇÖÕÓÚµÈÀ´Á˹ú¼ÊÁìÏȵÄÖÎÁÆ·½Ê½£¬Ò²Ï£Íû»ñµÃÉç»á¸÷½ç¶ÔÎÒÃÇÕâ¸öȺÌåµÄ¹Ø×¢£¬»ý¼«Íƶ¯´´ÐÂÒ©ÎïµÄ¿É¼°ÐÔ¡£¡±
´ËÇ°£¬È«ÇòÊ׸öÒ²ÊÇΨһ»ñÅúÖÎÁƳÉÈËÖÐÖضÈÌØÓ¦ÐÔƤÑ׵İÐÏòÉúÎïÖƼÁ´ï±ØÍ× ®´Ó6ÔÂ28ÈÕ»ñµÃ½ø¿ÚÒ©Îï×¢²áÖ¤£¨IDL£©µ½7ÔÂ22ÈÕ¹©Ò©£¬½öÓÃ25Ìì´´ÔìÁ˹úÄÚÉúÎïÖƼÁÉÏÊеÄ×î¿ìËٶȣ¬Ä¿Ç°ÒÑÔÚÈ«¹ú22¸öÊ¡¿ìËÙ¹©Ò©¡£
Ê׸öÌØÓ¦ÐÔƤÑ×°ÐÏòÉúÎïÖƼÁ´ï±ØÍ×(R)£¨¶ÈÆÕÀûÓȵ¥¿¹×¢ÉäÒº£©
Ϊ°ïÖú¼õÇỼÕß¾¼Ã¸ºµ££¬¾ÝÈüŵ·Æ·½Ãæ½éÉÜ£¬²ÎÓë¡°¹Ø°®±Ø´ï¡±»¼Õ߹ذ®ÏîÄ¿µÄ»¼Õߣ¬×¢²á³ÉΪ»áÔ±ºó²Î¼ÓþÐŽ¡¿µ×÷ΪͶ±£È˵ķÑÓò¹³¥ÐÍÍÅÌåÒ½ÁƱ£ÏÕ£¬ÔÚ±£ÏÕÆÚ¼äÄÚÿºÐ´ï±ØÍ× ®£¨2Ö§£©¿ÉÏí4000ÔªÀíÅâÉêÇ룬ÀÛ¼Æ×î¸ß¿É»ñµÃ20000ÔªµÄ±£ÏÕ½ð¶î¡£
Èüŵ·ÆÌØÒ©È«ÇòÊÂÒµ²¿ÖйúÇø×ܾÀíÍõ°Ø¿µ
Èüŵ·ÆÌØÒ©È«ÇòÊÂÒµ²¿ÖйúÇø×ܾÀíÍõ°Ø¿µ±íʾ£º¡°ÌáÇ°Á½Äê»ñÅú¡¢25Ì칩ҩ£¬´ï±ØÍ× ®¿ª´´ÁËеġ®Èüŵ·ÆÖйúËٶȡ¯¡£ÎÒÃDZü³Ö»¼ÕßΪÏÈ£¬¿ÆѧÁìÏȵÄÀíÄΪ±¥Êܼ²²¡À§Èŵ«È±·¦ÓÐЧÖÎÁƵĻ¼Õß´øÀ´¸ïÃüÐԵĴ´ÐÂÖÎÁÆ·½Ê½¡£´ï±ØÍ× ®µÄÉÏÊÐÊÇÈüŵ·ÆÌØÒ©ÔÚÖйúÃâÒßÑ×Ö¢ÁìÓòµÄ¿ª¶Ë¡£Î´À´£¬ÎÒÃǽ«È«Á¦¼ÓËÙ°üÀ¨ÃâÒßÑ×Ö¢¡¢º±¼û²¡¼°º±¼ûѪҺ²¡¡¢Ö×Áö¼°Éñ¾¿ÆѧÁìÓòÐÂÒ©ÔÚÖйúÉÏÊУ¬Âú×ãÖйú»¼Õßδ±»Âú×ãµÄ½¡¿µÐèÇó£¬Îª½¡¿µÖйú2030¹±Ï×Á¦Á¿¡£¡±
[1] Simpson E L, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. New England Journal of Medicine, 2016, 375(24): 2335-2348. |
[2] Silverberg J I, Yosipovitch G, Simpson E L, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS[J]. Journal of the American Academy of Dermatology, 2020. |
[3] Blauvelt, Andrew, et al. "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial."The Lancet389.10086 (2017): 2287-2303. |
[4] de Bruin Weller, M., et al. "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo controlled, randomized phase III clinical trial (LIBERTY AD CAFE)."British Journal of Dermatology178.5 (2018): 1083-1101. |
[5] Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey[J]. Allergy, 2018, 73(6): 1284-1293. |
ÉÏһƪ£ºÊ©Ä͵µçÆøÒÔÂÌÉ«ÖÇÄÜÖÆÔìÌáËÙÖйú¹¤ÒµÊý×Ö»¯×ªÐÍ
ÏÂһƪ£º×îºóÒ»Ò³
¹óÖÝÀúÊ·
¹óÖÝÀúÊ·
¹óÖÝÀúÊ·
QQ¹«ÖںŹØ×¢
ÐÂÀË΢²©¹Ø×¢
΢ÐźÅ:dd_gzw
¹¤ÉÌÍø¼à
³£ÎñÀíÊÂ
¹«°²±¸°¸
¹¤ÐŲ¿±¸°¸
°²È«ÁªÃË
ʵÃûÈÏÖ¤